Sugammadex Equity 100 Mg/Ml 100 mg Solution for injection
PDF Leaflet Revision Date: 25 March 2025
Clinical Summary
Quick overview from the medicine insert
Indication
Routine and immediate reversal of neuromuscular blockade induced by rocuronium or vecuronium.
Dosage (summary)
4 mg/kg for routine reversal; 16 mg/kg for immediate reversal.
Special Populations
- Renal impairment
- Hepatic impairment
- Elderly patients
- Obese patients
Pregnancy & Breastfeeding
Safety in pregnancy not established; caution advised in breastfeeding.
Key Drug Interactions
- Toremifene
- Fusidic acid
- Hormonal contraceptives
Contraindications
- Hypersensitivity to sugammadex
Common side effects
- Dysgeusia
- Cough
- Prolonged neuromuscular blockade
Counselling Points
- Monitor for recurrence of neuromuscular blockade.
- Ventilatory support may be required post-administration.
- Use caution with hormonal contraceptives.
Serious warnings
- Risk of hypersensitivity reactions
- Not for use with depolarising neuromuscular blockers
- Marked bradycardia observed
Important Disclaimer
The Sugammadex Equity 100 Mg/Ml 100 mg Solution for injection professional information leaflet below is the property of Equity Pharmaceuticals and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
